SLU-PP-915

Price range: $96.99 through $121.99

This product is intended for research and laboratory use only. It is not intended for human consumption, veterinary use, or any therapeutic applications. By purchasing this product, the buyer agrees to use it solely for research purposes in accordance with all applicable local, state, and federal regulations.

- +
SKU: ki-1779246076521-168 Category: Tags: , , , ,

SLU-PP-915

SLU-PP-915 is a synthetic small-molecule pan-agonist of the estrogen-related receptor family (ERRα, ERRβ, and ERRγ). Developed at Saint Louis University as a second-generation analog of SLU-PP-332, it was designed around a phenylboronic acid pharmacophore to retain ERR potency while improving microsomal metabolic stability and oral bioavailability. SLU-PP-915 has been characterized in preclinical models examining mitochondrial biogenesis, oxidative metabolism, and exercise-mimetic transcriptional programs.

This product is supplied for laboratory research use only.

Chemical Profile

  • Compound: SLU-PP-915
  • CAS Number: 2285432-92-8
  • Molecular Formula: C₁₇H₁₃BFNO₃S
  • Molecular Weight: 341.16 g/mol
  • Chemical Class: 2,5-disubstituted thiophene amide / phenylboronic acid
  • Appearance: Crystalline solid

Mechanism of Action

The estrogen-related receptors (ERRα, ERRβ, ERRγ) are orphan nuclear receptors that govern transcription of genes regulating mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation, and tricarboxylic acid cycle flux. SLU-PP-915 binds the ERR ligand-binding domain and drives transcriptional activation across all three isoforms with reported EC50 values of approximately 414 nM (ERRα), 435 nM (ERRβ), and 378 nM (ERRγ) in cell-based co-transfection assays. Reported activity is selective for the ERR subfamily, with no reported activity on the classical estrogen receptors ERα or ERβ.

In cellular and preclinical models, SLU-PP-915 upregulates canonical ERR target genes including PGC1α, PDK4, LDHA, and DDIT4. The compound has also been reported to increase expression of transcription factor EB (TFEB) and downstream autophagy-lysosomal markers (LAMP1, LAMP2, CTSD, MCOLN1) in cardiomyocyte and C2C12 myoblast systems.

Structural Relationship to SLU-PP-332

SLU-PP-915 emerged from a structure-based optimization campaign on the SLU-PP-332 chemotype. Substitution of the SLU-PP-332 phenolic hydrogen-bond donor with a phenylboronic acid group preserved pan-ERR activity while substantially improving stability in human and mouse liver microsomes. The boronic acid analog also exhibits oral bioavailability in murine models, where the parent compound is limited to parenteral administration.

Preclinical Research Context

Published investigations involving SLU-PP-915 have explored:

  • Aerobic exercise capacity in murine treadmill models, including running distance and time-to-exhaustion endpoints
  • Mitochondrial gene expression and oxidative phosphorylation in skeletal muscle
  • Cardiac fatty acid metabolism and mitochondrial function in transaortic constriction (TAC) pressure-overload models of heart failure
  • Synergistic transcriptional effects when combined with exercise training
  • Autophagic flux through the TFEB-lysosomal axis in cardiomyocytes

These applications position SLU-PP-915 as a chemical probe for ERR pharmacology and a comparator to first-generation pan-ERR agonists such as SLU-PP-332.

Handling and Storage

Store sealed at –20 °C, protected from light and moisture. Soluble in DMSO for in vitro work. Vehicle formulations reported in the preclinical literature for in vivo delivery include DMSO/PEG-300/Tween-80 and DMSO/SBE-β-CD systems.

Quality Control

Every lot of SLU-PP-915 is independently verified through third-party COA testing prior to release. Identity is confirmed by NMR and mass spectrometry; purity is quantified by HPLC. Lot-specific COAs are available through the Kimera Chems COA database.

Research Use Only

This product is intended for research and laboratory use only. It is not intended for human consumption, veterinary use, or any therapeutic applications. By purchasing this product, the buyer agrees to use it solely for research purposes in accordance with all applicable local, state, and federal regulations.

CAS Number 2285432-92-8
IUPAC Name [3-[5-[(2-fluorophenyl)carbamoyl]thiophen-2-yl]phenyl]boronic acid
Molecular Formula C₁₇H₁₃BFNO₃S
Molecular Weight 341.16
Dry-Fill Capsule Concentration 10mg
Liquid Concentration And Solution 20mg/ml DMSO, PEG-400

form

, ,

Shopping Cart
Scroll to Top